Global Duchenne Muscular Dystrophy Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Duchenne Muscular Dystrophy Therapeutics Market Growth (Status and Outlook) 2023-2029

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

LPI (LP Information)' newest research report, the “Duchenne Muscular Dystrophy Therapeutics Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy Therapeutics sales for 2023 through 2029. With Duchenne Muscular Dystrophy Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy Therapeutics.

The global Duchenne Muscular Dystrophy Therapeutics market size is projected to grow from US$ 1300.3 million in 2022 to US$ 5197.3 million in 2029; it is expected to grow at a CAGR of 21.9% from 2023 to 2029.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort

Segmentation by application
Hospitals
Clinics
Home Care

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)

Please note: The report will take approximately 2 business days to prepare and deliver.